biomedicina slovenica

re="Breast Cancer Res Treat" : 21

  1. Templeton Arnoud; Ocaña Alberto; Šeruga Boštjan; Vera-Badillo Francisco; Carlsson Lindsay; Bedard Philippe L.; Amir Eitan
    Management of small HER2 overexpressing tumours
    2012 ►
  2. Vardy JL; Pond Gregory Russell; Dodd Anna; Warr David; Šeruga Boštjan; Clemons Mark J; Bordeleau Louise; Goodwin Peter C; Tannock Ian
    A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 h following adjuvant chemotherapy for breast cancer
    2012 ►
  3. Merlo Domenico Franco; Primic-Žakelj Maja
    Breast cancer incidence trends in European women aged 20-39 years at diagnosis
    2012 ►
  4. Šeruga Boštjan; Amir Eitan
    Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis
    2010 ►
  5. Borštnar Simona; Sadikov Aleksander; Možina Barbara; Čufer Tanja
    High levels of uPA and PAI-1 predict a good response to anthracyclines
    2010 ►
  6. Perhavec Andrež; Pohar-Perme Maja; Hočevar Marko; Bešić Nikola; Žgajnar Janez
    Ljubljana nomograms for predicting the likelihood of non-sentinel lymph node metastases in breast cancer patients with a positive sentinel lymph node
    2010 ►
  7. Korde Larissa A; Lusa Lara; McShane Lisa; Lebowitz Peter F; Lukes LuAnne; Camphausen Kevin; Parker Joel S; Swain Sandra M; Hunter Kent; Zujewski Jo Anne
    Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer
    2009 ►
  8. Golouh R; Čufer T; Sadikov A; Nussdorfer P; Usher PA; Brunner N; Schmitt M; Lesche R; Maier S; Timmermans M; Foekens JA; Martens JW
    The prognostic value of Stathmin-1, S100A2, and SYK proteins in ER-positive primary breast cancer patients treated with adjuvant tamoxifen monotherapy: an immunohistochemical study
    2008 ►
  9. Thurlimann Beat; Price Karen N; Gelber Richard D; Holmberg Stig B; Crivellari Diana; Colleoni Marco; Collins John; Forbes John F; Castiglione-Gertsch Monica; Lindtner J; Eržen D; Čufer T; Červek J; Cerar O; Zakotnik B; Majdič E; Golouh R; Lamovec J; Jančar J; Vrhovec I; Kramberger M
    Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93
    2009 ►
  10. Zhang Yi; Sieuwerts Anieta M; McGreevy Michelle; Casey Graham; Čufer Tanja; Paradiso Angelo; Harbeck Nadia; Span Paul N; Hicks David G; Golouh Rastko
    The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy
    2009 ►
  11. Pagani O; Gelber S; Simoncini E; Castiglione-Gertsch M; Price KN; Gelber RD; Holmberg SB; Crivellari D; Lindtner J; Čufer T
    Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93
    2009 ►
  12. Karina M; Čufer Tanja
    Preliminary safety data of the EORTC 10994/BIG 00-01 neoadjuvant trial comparing 3 cycles of docetaxel followed by 3 cycles of epirubicin-docetaxel versus 6 cycles of FEC 100 in patients with locally advanced/inflammatory or large operable breast cancer
    2006 ►
  13. Golouh Rastko; Čufer Tanja; Sadikov A; Nusdorfer P; Usher P; Bruenner N; Schmitt M; Harbeck N; Lesche R; Meier S
    Stathmin-1 protein expression is associated with disease recurrence in tamoxifen-treated steroid hormone receptor positive early breast cancer: an immunohistochemical study
    2006 ►
  14. Debrakeleer S.; De Greve Jacques; Krajc Mateja; Sermijn E.; Fontaine C.; Goelen Guido; Bonduelle M.; Novaković Srdjan; Teugels Erik
    Germline mutation of the BARD1 ankyrin domain in a non-BRCA1/2 breast cancer family
    2006 ►
  15. Žgajnar Janez; Hočevar Marko; Podkrajšek Maja; Hertl Kristijana; Frković-Grazio Snježana; Vidmar Gaj; Bešić Nikola
    Patients with preoperatively ultrasonically uninvolved axillary lymph nodes: a distinct subgroup of early patients
    2006 ►
  16. Borštnar S; Vrhovec I; Čufer T
    High levels of uPA and PAI-1 predicts a good response to antracyclines
    2004 ►
  17. Cauley Jane A; Norton Larry; Lippman Marc E; Eckert Stephen; Krueger Kathryn A; Purdie David W; Farrerons Jordi; Karasik Avraham; Mellstrom Dan; Kocijančič Andreja
    Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial
    2001 ►
  18. Bonnefoi H; Biganzoli L; Čufer T; Mauriac L; Hamilton A; Schaefer P; Picart M
    An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer
    2001 ►
  19. Levičar N; Blejec A; Kos J; Golouh R; Vrhovec I; Frkovič-Gracio S; Lah TT
    Prognostic impact of serine and cysteine proteinases and their inhibitors in breast carcinoma
    1999 ►
  20. Bonnefoi H; Biganzoli L; Čufer T; Hamilton A; Mauriac L; Van Hoorebeeck I; Piccart M
    A feasibility study of epirubicin (E) in combination with cyclophosphamide (C) and infusional 5-fluorouracil (F-infu)(CEF-infu) as primary treatment of large operable (LO) or locally advanced/inflammatory (LA/I) breast cancer (BC)
    1999 ►
  21. Lah Tamara T; Calaf Gloria; Kalman Endre; Shinde Balasahib G; Somers Robert; Estrada Sandino; Salero Enrique; Russo Jose; Daskal Ierachmiel
    Cathepsins D, B, and L in transformed breast epithelial cells
    1996 ►

Nova poizvedba      Pripombe      Na vrh strani                        Inštitut za biostatistiko in medicinsko informatiko